CStone to build Global R&D HQ and Industrialization base in China
The signing ceremony for CStone Pharmaceuticals' Global R&D Headquarters and Industrialization Base took place in Suzhou on 6 August 2019. The event marks the building of yet another state-of-the-art research and development (R&D) centre and manufacturing facility in Suzhou Industrial Park. The signatory parties at the ceremony included Mr. Lixin Ding, Deputy Secretary of Suzhou Industrial Park's (SIP) Party and Union Committee and Director of the Suzhou Industrial Park Administrative Committee (SIPAC); Mr. Xiaoming Lin, Member of the SIP's Party and Union Committee, Deputy Director of SIPAC and Head of SIPAC's Organization Department; Mr. Xiaomin Ye, Chairman of Suzhou Sungent Holding Group; Mr. Yue Kang, Vice Chairman and General Manager of Suzhou Sungent Holding Group; and Dr. Frank Jiang, Chairman and CEO of CStone.
The SIP provided strong support for both the Project's investment and construction plan. According to the agreement, the construction of the site, with a planned building area of approximately 100,000m2, will be commissioned to a third party and is scheduled to break ground in 2020. Once completed, the complex will be equipped with integrated capabilities for R&D, Pilot Plant, and full commercial-scale manufacturing, which will have a production capacity of 26,000L for macromolecule biologics and 1 billion tablets and capsules for small molecule drugs.